Results 101 to 110 of about 649,845 (314)

Validación del efecto de remediación y refinación catalítica de los catalizadores EcoEvol y su efecto en la mejora en la performance de motores a combustión interna

Ingeniería Industrial, 2016
Los motores a combustión interna son usados para distintas actividades económicas como el transporte, la generación de electricidad, minería, entre otras aplicaciones.
Darío Eder Lazo-Hoyos, Rodrigo Coquis Sánchez-Concha   +1 more
doaj  

KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer

Molecular Oncology, EarlyView.
Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan, Veronika M Metzler, Simone de Brot, Corinne L Woodcock, Anna E Harris, Jennifer Lothion‐Roy, Emeli M Nilsson, Atara Ntekim, Michael S Toss, Jenny L Persson, Francesca Khani, Brian D Robinson, Lorraine J Gudas, Emad Rakha, David M Heery, Catrin S Rutland, Nigel P Mongan   +16 more
wiley   +1 more source

The Connecticut Innovations blog. 2011: Aug. [PDF]

, 2011
Irregular; Began with Sept.

core  

Crucial aspects for maintaining rAAV stability

Scientific Reports
The storage of rAAV vectors for gene therapy applications is critical for ensuring a constant product quality and defined amount of medication at the time of administration.
Johannes Lengler, Mia Gavrila, Janina Brandis, Kristina Palavra, Felix Dieringer, Sabine Unterthurner, Felix Fuchsberger, Barbara Kraus, Juan A. Hernandez Bort   +8 more
doaj   +1 more source

Heterozygous loss‐of‐function alleles associate the conserved 3′‐5′ exoribonuclease EXOSC10 with hypersensitivity to the anticancer drug 5‐fluorouracil

Molecular Oncology, EarlyView.
EXOSC10, an essential nuclear RNA exosome‐associated 3′‐5′ exoribonuclease, is inhibited by the anticancer drug 5‐fluorouracil (5‐FU), and EXOSC10 depletion increases 5‐FU sensitivity. The colon‐cancer variant EXOSC10S402T, located in a proteolysis motif, is stable and nuclear but nonfunctional in vivo.
Radhika Sain, Yann Le Page, Frédéric Percevault, Emmanuelle Becker, Luc Negroni, Almudena Fernandez, Marta Cantero, Diego Muñoz‐Santos, Lluís Montoliu, Cyrille Garnier, Michael Primig   +10 more
wiley   +1 more source

The Connecticut Innovations blog. 2011: Dec. [PDF]

, 2011
Irregular; Began with Sept.

core  

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

The Connecticut Innovations blog. 2011: Jun. [PDF]

, 2011
Irregular; Began with Sept.

core  

Low-dose radiotherapy enhances the efficacy of PD-L1 blockade and induces the abscopal effect

Journal for ImmunoTherapy of Cancer
Background Low-dose radiotherapy (RT) is a promising treatment likely to increase the efficacy of immunotherapy, including programmed cell death ligand 1 (PD-L1) blockade, in cancer therapy.
Pierre-Antoine Laurent, Eric Deutsch, Charlotte Robert, Antonin Levy, Michele Mondini, Marine Gerbé De Thoré, Winchygn Liu, Lydia Meziani, Céline Clémenson, Flavie Naulin, Liu Shi, Lisa Bouarroudj, Nathan Benzazon, Marine Aglave, Paul Bergeron, Lisa Sitterlé, Daphné Morel   +16 more
doaj   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

Molecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata, Koji Ando, Hirofumi Hasuda, Koshi Mimori, Elizabeth C. Unan, Siddhartha Pulukuri, Aahana Tiku, Allison Berger, Eiji Oki, Ajit Bharti, Tomoharu Yoshizumi   +10 more
wiley   +1 more source